PedAM
Pediatric Disease Annotations & Medicines
| plasmacytoma | ||||
| Disease ID | 372 |
|---|---|
| Disease | plasmacytoma |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:25) HP:0006775 | Multiple myeloma | 24 HP:0001271 | Polyneuropathy | 2 HP:0000405 | Conductive hearing loss | 1 HP:0002953 | Vertebral compression fractures | 1 HP:0002202 | Pleural effusion | 1 HP:0100727 | Histiocytosis | 1 HP:0001138 | Damaged optic nerve | 1 HP:0002584 | Intestinal hemorrhage | 1 HP:0002665 | Lymphoma | 1 HP:0005523 | Lymphoproliferative disorder | 1 HP:0005202 | Helicobacter pylori infection | 1 HP:0030731 | Carcinoma | 1 HP:0002326 | TIA | 1 HP:0030078 | Lung adenocarcinoma | 1 HP:0002239 | Gastrointestinal hemorrhage | 1 HP:0000620 | Dacrocystitis | 1 HP:0003003 | Colon cancer | 1 HP:0011034 | Amyloid disease | 1 HP:0002664 | Neoplasia | 1 HP:0000501 | Glaucoma | 1 HP:0000083 | Renal insufficiency | 1 HP:0002176 | Spinal cord compression | 1 HP:0000952 | Yellow skin | 1 HP:0012189 | Hodgkin disease | 1 HP:0002756 | Pathologic fracture | 1 |
| Disease ID | 372 |
|---|---|
| Disease | plasmacytoma |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:22) C2364133 | infection C1963154 | renal failure C1565489 | renal insufficiency C1409177 | paramyloidosis C1373218 | immunosuppression C1000483 | anemia C0878544 | cardiomyopathy C0850497 | immune deficiency C0752303 | urological manifestations C0563307 | igd myeloma C0432487 | post-transplant lymphoproliferative disorder C0400979 | biliary tract obstruction C0281479 | systemic amyloidosis C0268381 | al amyloidosis C0152025 | polyneuropathy C0030489 | paraproteinemia C0026764 | myeloma C0025202 | malignant melanomas C0023795 | hyalinosis cutis et mucosae C0021051 | immunodeficiency C0007137 | squamous cell carcinoma C0002726 | amyloidosis |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:4) C0026764 | myeloma | 17 C0152025 | polyneuropathy | 2 C0002726 | amyloidosis | 1 C0035078 | renal failure | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs113488022 | 26071465 | 673 | BRAF | umls:C0032131 | BeFree | We analyzed 121 cases, including 26 HCLs, 52 non-HCL splenic lymphomas, 22 chronic lymphocytic leukemias/small lymphocytic lymphomas (CLLs/SLLs), and 21 plasma cell neoplasms (PCNs) for BRAF V600E expression by IHC. | 0.000271442 | 2015 | BRAF | 7 | 140753336 | A | T,G,C |
| rs2720709 | 17395743 | 5820 | PVT1 | umls:C0032131 | BeFree | These SNPs were genotyped in individuals comprising each pool, and strong evidence for association was found with rs2720709 (P = 0.000021; odds ratio 2.57 [95% CI 1.66-3.96]), which is located in the plasmacytoma variant translocation gene PVT1. | 0.001085767 | 2007 | PVT1 | 8 | 128046110 | G | A |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:3) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0032131 | bortezomib | D000069286 | - | plasmacytoma | MESH:D010954 | therapeutic | 19259673 | ||
| C0032131 | rosiglitazone | C089730 | - | plasmacytoma | MESH:D010954 | therapeutic | 19731824 | ||
| C0032131 | tretinoin | D014212 | 302-79-4 | plasmacytoma | MESH:D010954 | therapeutic | 19731824 | ||
FDA approved drug and dosage information(Total Drugs:1) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D010954 | velcade | bortezomib | 3.5MG/VIAL | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | Prescription | None | Yes | Yes |
FDA labeling changes(Total Drugs:1) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D010954 | 09/14/2015 | velcade | bortezomib | Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) | Effectiveness in pediatric patients with relapsed pre-B ALL has not been established. The activity and safety of Velcade in combination with intensive reinduction chemotherapy was evaluated in pediatric and young adult patients with lymphoid malignancies. There were 140 patients with ALL or LL enrolled and evaluated for safety. No new safety concerns were observed | Labeling | B | - | - | - | Millennium Pharmaceuticals, Inc. | - | FALSE |